NCT00971256

Brief Summary

Review bladder cancer patients and form a database in regards to urine cytology.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2009

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2009

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

September 2, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 3, 2009

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2010

Completed
Last Updated

November 23, 2011

Status Verified

November 1, 2011

Enrollment Period

1 year

First QC Date

September 2, 2009

Last Update Submit

November 22, 2011

Conditions

Bladder Cancer

Keywords

BladderCancerCytology

Outcome Measures

Primary Outcomes (1)

  • Review bladder cancer patients and form a database in regards to urine cytology.

    1 month

Study Arms (1)

Bladder cancer patients

Bladder cancer patients from one Beaumont Urologist.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with bladder cancer.

You may qualify if:

  • Bladder cancer patients from Dr. Jay Hollander's private practice.

You may not qualify if:

  • Patients with diagnosis of bladder cancer without initial cytology available.
  • Patients who received outside nephrectomy or cystectomy without pathology available.
  • Those who had recurrence without cytology results available.
  • Those who were followed by Dr Hollander and another urologist in which records are missing for a significant number of follow ups.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Urinary Bladder NeoplasmsNeoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Joseph Mashni, MD

    Beaumont Hospitals

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 2, 2009

First Posted

September 3, 2009

Study Start

September 1, 2009

Primary Completion

September 1, 2010

Study Completion

September 1, 2010

Last Updated

November 23, 2011

Record last verified: 2011-11